{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T23:46:56Z","timestamp":1793144816054,"version":"4.5.0"},"reference-count":56,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,12]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Voriconazole (VRZ) is a second-generation triazole antifungal agent with broad-spectrum activity. It is available in both intravenous and oral formulations, and is primarily indicated for treating invasive aspergillosis. The most commonly used dose for adults is 4 mg\/kg or 200 mg twice daily. VRZ presents nonlinear pharmacokinetics in adults, whereas drug\u2013drug interactions and cytochrome P450 2C19 (CYP2C19) polymorphism are of great concern for VRZ. Because the liquid chromatography method has been widely used for measuring VRZ blood concentration, and target VRZ blood concentration has been recommended in some guidelines regarding efficacy and safety, therapeutic drug monitoring is considered as a useful tool for VRZ-individualized medication. Also, the CYP2C19 genotype test is available for guiding relevant drugs use in some health care facilities. Our objective was to develop an evidence-based practice guideline for VRZ-individualized medication.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We followed the latest guideline definition from the Institute of Medicine and referred to the World Health Organization handbook for guideline development. The guideline was initially registered in the International Practice Guidelines Registry Platform (IPGRP-2015CN001). The guideline is, in principle, targeted at all Chinese health care providers. The quality of evidence and strength of the recommendations were assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) method.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Twenty-six recommendations were formulated regarding therapeutic drug monitoring, special groups of patients, drug safety, off-indication use, and drug\u2013drug interactions. Of them, 12 were strong recommendations. Most quality of evidence was low, very low, or expert opinions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>We developed an evidence-based practice guideline for VRZ-individualized medication, which provided comprehensive and practical recommendations for health care providers. The development of the guideline exposed several research gaps to improve VRZ use.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ftd.0000000000000561","type":"journal-article","created":{"date-parts":[[2018,9,6]],"date-time":"2018-09-06T08:13:55Z","timestamp":1536221635000},"page":"663-674","source":"Crossref","is-referenced-by-count":123,"title":["Individualized Medication of Voriconazole: A Practice Guideline of the Division of Therapeutic Drug Monitoring, Chinese Pharmacological Society"],"prefix":"10.1097","volume":"40","author":[{"given":"Ken","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Peking University Third Hospital;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianglin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Pharmaceutical Department, China-Japan Friendship Hospital;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Ke","sequence":"additional","affiliation":[{"name":"Department of Haematology, Peking University Third Hospital;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanhua","family":"Du","sequence":"additional","affiliation":[{"name":"National Center for Pharmaceutical Screening, Institute of Materia Medica, Chinese Academy of Medical Sciences, Beijing, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kehu","family":"Yang","sequence":"additional","affiliation":[{"name":"Evidence-Based Medicine Center, Lanzhou University; and"},{"name":"Chinese GRADE Center, Lanzhou University, Lanzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suodi","family":"Zhai","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Peking University Third Hospital;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the Guideline Steering Committee, the Guideline Consensus Panel, and the Guideline Development Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230814","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/civ933","article-title":"Clinical practice guideline for the management of candidiasis: 2016 Update by the Infectious Diseases Society of America","volume":"62","author":"Pappas","year":"2016","journal-title":"Clin Infect Dis."},{"key":"R2-20230814","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice guidelines for the diagnosis and management of aspergillosis: 2016 Update by the Infectious Diseases Society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin Infect Dis."},{"key":"R3-20230814","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.ijantimicag.2017.03.021","article-title":"Comparing the safety and efficacy of voriconazole versus posaconazole in the prevention of invasive fungal infections in high-risk patients with hematological malignancies","volume":"50","author":"Hachem","year":"2017","journal-title":"Int J Antimicrob Agents."},{"key":"R4-20230814","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa020191","article-title":"Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis","volume":"347","author":"Herbrecht","year":"2002","journal-title":"N Engl J Med."},{"key":"R5-20230814","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1111\/ejh.12641","article-title":"Comparison of micafungin and voriconazole as empirical antifungal therapies in febrile neutropenic patients with hematological disorders: a randomized controlled trial","volume":"96","author":"Oyake","year":"2016","journal-title":"Eur J Haematol."},{"key":"R7-20230814","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.bbmt.2015.03.018","article-title":"Epidemiology, management, and outcome of invasive fungal disease in patients undergoing hematopoietic stem cell transplantation in China: a multicenter prospective observational study","volume":"21","author":"Sun","year":"2015","journal-title":"Biol Blood Marrow Transpl."},{"key":"R8-20230814","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s13277-014-2649-7","article-title":"Invasive fungal infection in patients receiving chemotherapy for hematological malignancy: a multicenter, prospective, observational study in China","volume":"36","author":"Sun","year":"2015","journal-title":"Tumour Biol."},{"key":"R9-20230814","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1097\/FTD.0b013e31817b1a95","article-title":"Therapeutic drug monitoring of voriconazole","volume":"30","author":"Bruggemann","year":"2008","journal-title":"Ther Drug Monit."},{"key":"R10-20230814","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1517\/13543784.11.3.409","article-title":"Review of the safety and efficacy of voriconazole","volume":"11","author":"Hoffman","year":"2002","journal-title":"Expert Opin Investig Drugs."},{"key":"R11-20230814","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1124\/dmd.31.5.540","article-title":"Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole","volume":"31","author":"Hyland","year":"2003","journal-title":"Drug Metab Dispos."},{"key":"R12-20230814","doi-asserted-by":"crossref","first-page":"649","DOI":"10.2165\/00003088-200645070-00002","article-title":"Pharmacokinetic\/pharmacodynamic profile of voriconazole","volume":"45","author":"Theuretzbacher","year":"2006","journal-title":"Clin Pharmacokinet."},{"key":"R13-20230814","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/cpt.583","article-title":"Clinical pharmacogenetics implementation consortium (CPIC) guidelines for CYP2C19 and voriconazole therapy","volume":"102","author":"Moriyama","year":"2017","journal-title":"Clin Pharmacol Ther."},{"key":"R14-20230814","first-page":"427","article-title":"Genotype frequencies of CYP2C19 in healthy Asian populations: a synthetic analysis","volume":"14","author":"Zhang","year":"2014","journal-title":"Chin J Evid-based Med."},{"key":"R17-20230814","first-page":"289","article-title":"A protocol of practice guideline for individualized medication of voriconazole","volume":"26","author":"Chen","year":"2017","journal-title":"Chin J Pharmacoepidemiol."},{"key":"R18-20230814","first-page":"368","article-title":"Using Delphi method to determine the questions and outcomes included in the practice guidelines for individualized medication of voriconazole","volume":"32","author":"Chen","year":"2016","journal-title":"Chin J Clin Pharmacol."},{"key":"R19-20230814","first-page":"456","article-title":"Investigation of willingness in individualized medication of voriconazole in patients with fungal infections","volume":"33","author":"Xu","year":"2017","journal-title":"Chin J Clin Pharmacol."},{"key":"R20-20230814","first-page":"265","article-title":"Discussion of development of Chinese practice guideline for individualized medication of voriconazole","volume":"33","author":"Chen","year":"2017","journal-title":"Chin J Clin Pharmacol."},{"key":"R21-20230814","first-page":"143","article-title":"Chinese practice guideline for individualized medication of voriconazole: recommendations external review","volume":"26","author":"Chen","year":"2017","journal-title":"Chin J Pharmacoepidemiol."},{"key":"R22-20230814","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ."},{"key":"R23-20230814","first-page":"202","article-title":"Effect of cytochrome P-450 inhibitors on pharmacokinetics and safety of voriconazole","volume":"26","author":"Yang","year":"2017","journal-title":"J Chin Pharm Sci."},{"key":"R24-20230814","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/jcpt.12493","article-title":"The influence of combination use of CYP450 inducers on the pharmacokinetics of voriconazole: a systematic review","volume":"42","author":"Li","year":"2017","journal-title":"J Clin Pharm Ther."},{"key":"R25-20230814","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1007\/s00228-016-2089-y","article-title":"Effect of cytochrome P450 2C19 polymorphisms on the clinical outcomes of voriconazole: a systematic review and meta-analysis","volume":"72","author":"Li","year":"2016","journal-title":"Eur J Clin Pharmacol."},{"key":"R26-20230814","first-page":"267","article-title":"Effect of cytochrome P450 2C19 genotype on pharmacokinetics of voriconazole in healthy volunteers: a systematic review and meta-analysis","volume":"32","author":"Li","year":"2016","journal-title":"Chin J Clin Pharmacol."},{"key":"R27-20230814","first-page":"261","article-title":"Difference of efficacy, safety and pharmacokinetics of voriconazole in different age: a systematic review","volume":"32","author":"Guo","year":"2016","journal-title":"Chin J Clin Pharmacol."},{"key":"R28-20230814","first-page":"80","article-title":"Efficacy and safety of therapeutic drug monitoring of voriconazole: a systematic review","volume":"33","author":"Chen","year":"2017","journal-title":"Chin J Clin Pharmacol."},{"key":"R29-20230814","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1124\/dmd.109.029769","article-title":"In vitro hepatic metabolism explains higher clearance of voriconazole in children versus adults: role of CYP2C19 and flavin-containing monooxygenase 3","volume":"38","author":"Yanni","year":"2010","journal-title":"Drug Metab Dispos."},{"key":"R30-20230814","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1093\/jac\/dkw045","article-title":"Trough concentration of voriconazole and its relationship with efficacy and safety: a systematic review and meta-analysis","volume":"71","author":"Jin","year":"2016","journal-title":"J Antimicrob Chemother."},{"key":"R31-20230814","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1128\/AAC.05761-11","article-title":"Integrated population pharmacokinetic analysis of voriconazole in children, adolescents, and adults","volume":"56","author":"Friberg","year":"2012","journal-title":"Antimicrob Agents Chemother."},{"key":"R32-20230814","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1128\/AAC.00702-11","article-title":"Population pharmacokinetics of voriconazole in adults","volume":"56","author":"Hope","year":"2012","journal-title":"Antimicrob Agents Chemother."},{"key":"R33-20230814","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1128\/AAC.46.8.2546-2553.2002","article-title":"Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens","volume":"46","author":"Purkins","year":"2002","journal-title":"Antimicrob Agents Chemother."},{"key":"R34-20230814","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1177\/00912700222011445","article-title":"Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study","volume":"42","author":"Lazarus","year":"2002","journal-title":"J Clin Pharmacol."},{"key":"R35-20230814","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1046\/j.1365-2125.2003.01993.x","article-title":"Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety","volume":"56","author":"Purkins","year":"2003","journal-title":"Br J Clin Pharmacol."},{"key":"R36-20230814","doi-asserted-by":"crossref","first-page":"557","DOI":"10.3109\/08880018.2015.1088905","article-title":"The clinical significance of voriconazole therapeutic drug monitoring in children with invasive fungal infections","volume":"32","author":"Kang","year":"2015","journal-title":"Pediatr Hematol Oncol."},{"key":"R37-20230814","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1093\/cid\/cis437","article-title":"Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics-based analysis of adult patients with invasive fungal infections","volume":"55","author":"Pascual","year":"2012","journal-title":"Clin Infect Dis."},{"key":"R38-20230814","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1086\/524669","article-title":"Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes","volume":"46","author":"Pascual","year":"2008","journal-title":"Clin Infect Dis."},{"key":"R39-20230814","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/cid\/cis599","article-title":"The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial","volume":"55","author":"Park","year":"2012","journal-title":"Clin Infect Dis."},{"key":"R40-20230814","first-page":"779","article-title":"Preliminary experience of routine voriconazole TDM in a tertiary care centre","volume":"34","author":"Vanstraelen","year":"2012","journal-title":"Int J Clin Pharm."},{"key":"R42-20230814","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jinf.2012.09.011","article-title":"Voriconazole hepatotoxicity in severe liver dysfunction","volume":"66","author":"Solis-Munoz","year":"2013","journal-title":"J Infect."},{"key":"R43-20230814","first-page":"548","article-title":"Efficacy of voriconazole in treating severe hepatitis with invasive pulmonary aspergillosis","volume":"39","author":"Liu","year":"2013","journal-title":"Jiangsu Med J."},{"key":"R44-20230814","first-page":"1","article-title":"Surgery and portal hypertension","volume":"1","author":"Child","year":"1964","journal-title":"Major Probl Clin Surg."},{"key":"R45-20230814","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/bjs.1800600817","article-title":"Transection of the oesophagus for bleeding oesophageal varices","volume":"60","author":"Pugh","year":"1973","journal-title":"Br J Surg."},{"key":"R46-20230814","first-page":"16006","article-title":"Efficacy and safety comparison between intravenous and oral voriconazole: a systematic review and meta-analysis","volume":"9","author":"Wen","year":"2016","journal-title":"Int J Clin Exp Med."},{"key":"R47-20230814","first-page":"729","article-title":"Compassionate use of voriconazole in newborn infants diagnosed with severe invasive fungal sepsis","volume":"17","author":"Celik","year":"2013","journal-title":"Eur Rev Med Pharmacol Sci."},{"key":"R48-20230814","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1097\/INF.0b013e31824acc33","article-title":"Therapeutic monitoring of voriconazole in children less than three years of age: a case report and summary of voriconazole concentrations for ten children","volume":"31","author":"Doby","year":"2012","journal-title":"Pediatr Infect Dis J."},{"key":"R49-20230814","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1128\/AAC.01540-12","article-title":"Highly variable plasma concentrations of voriconazole in pediatric hematopoietic stem cell transplantation patients","volume":"57","author":"Bartelink","year":"2013","journal-title":"Antimicrob Agents Chemother."},{"key":"R50-20230814","first-page":"1197","article-title":"Drug interactions and adverse events associated with antimycotic drugs used for invasive aspergillosis in hematopoietic SCT","volume":"45","author":"Egger","year":"2010","journal-title":"BMT."},{"key":"R51-20230814","first-page":"657","article-title":"Voriconazole overdose causes acute kidney injury and severe drug interaction with tacrolimus","volume":"51","author":"Connors","year":"2013","journal-title":"Clin Toxicol."},{"key":"R54-20230814","first-page":"1706","article-title":"Analysis of off-indication use of voriconazole","volume":"33","author":"Liang","year":"2017","journal-title":"Chin J Clin Pharmacol."},{"key":"R55-20230814","first-page":"785","article-title":"Influence of voriconazole on pharmacokinetics and safety of combined drugs: a systematic review","volume":"25","author":"Liu","year":"2016","journal-title":"J Chin Pharm Sci."},{"key":"R56-20230814","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1177\/0091270007309703","article-title":"Pharmacokinetic interaction between voriconazole and efavirenz at steady state in healthy male subjects","volume":"48","author":"Liu","year":"2008","journal-title":"J Clin Pharmacol."},{"key":"R58-20230814","doi-asserted-by":"crossref","first-page":"3124","DOI":"10.1093\/jac\/dkv224","article-title":"Budget impact analysis of CYP2C19-guided voriconazole prophylaxis in AML","volume":"70","author":"Mason","year":"2015","journal-title":"J Antimicrob Chemother."},{"key":"R59-20230814","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ijantimicag.2009.01.008","article-title":"Correlation between voriconazole trough plasma concentration and hepatotoxicity in patients with different CYP2C19 genotypes","volume":"34","author":"Matsumoto","year":"2009","journal-title":"Int J Antimicrob Agents."},{"key":"R60-20230814","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s00228-010-0914-2","article-title":"Effect of cytochrome P450 2C19 genotype on voriconazole exposure in cystic fibrosis lung transplant patients","volume":"67","author":"Berge","year":"2011","journal-title":"Eur J Clin Pharmacol."},{"key":"R61-20230814","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ijantimicag.2014.07.013","article-title":"Efficacy and safety of voriconazole and CYP2C19 polymorphism for optimised dosage regimens in patients with invasive fungal infections","volume":"44","author":"Wang","year":"2014","journal-title":"Int J Antimicrob.Agents."},{"key":"R62-20230814","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s10156-013-0607-8","article-title":"Practice guidelines for therapeutic drug monitoring of voriconazole: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring","volume":"19","author":"Hamada","year":"2013","journal-title":"J Infect Chemother."},{"key":"R63-20230814","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1093\/jac\/dkt508","article-title":"Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology","volume":"69","author":"Ashbee","year":"2014","journal-title":"J Antimicrob Chemother."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00007691-201812000-00001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T18:13:37Z","timestamp":1692036817000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-201812000-00001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":56,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000561","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]}}}